BILL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Given the mixed financial performance, neutral technical indicators, and lack of strong proprietary trading signals, BILL Holdings Inc is not a strong buy for a beginner investor with a long-term strategy at this time. The stock's recent price volatility and uncertain growth trajectory suggest waiting for clearer positive catalysts or improved financial metrics before investing.
The MACD is positive at 0.809 but contracting, suggesting weakening momentum. RSI at 52.2 is neutral, indicating no clear overbought or oversold conditions. Moving averages are converging, reflecting indecision in price trends. Key support is at 37.432, and resistance is at 50.338, with the current price near the pivot level of 43.885.
Hedge funds are significantly increasing their positions in BILL, with a 111.02% increase in buying activity last quarter.
Acquisition talks with Hellman & Friedman have driven optimism and a recent surge in stock price.
Strong Q2 revenue growth of 14.37% YoY and a share buyback initiative.
Net income dropped by -107.71% YoY, and EPS fell by -109.38% YoY, indicating profitability challenges.
Gross margin declined by 2.06% YoY, reflecting potential cost pressures.
Analysts have lowered price targets, with some maintaining neutral or market perform ratings.
Broader market concerns about AI disruption in the software sector.
In Q2 2026, BILL reported revenue growth of 14.37% YoY to $414.7 million. However, net income dropped to -$2.59 million, down -107.71% YoY, and EPS fell to -$0.03, down -109.38% YoY. Gross margin also declined slightly to 77.82%. While revenue growth is positive, the significant decline in profitability is a concern.
Analyst sentiment is mixed. While firms like Truist and Canaccord raised price targets and reiterated Buy ratings, others like Goldman Sachs and Jefferies lowered their targets but maintained Buy ratings. Some firms, such as Evercore ISI and BMO Capital, have neutral or market perform ratings, reflecting cautious optimism. Recent price targets range from $42 to $77.
